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Our patient was diagnosed with a stage IIA, triple negative, invasive
ductal carcinoma of the breast at age 33. Genetic testing conﬁrmed a
BRCA1 Exon2 185 delAG mutation. Pelvic ultrasound was normal. She
received adjuvant systemic chemotherapy and adjuvant radiation to her
affected breast. Four years later she was diagnosed with a contralateral
T1aN0M0 inﬁltrating ductal carcinoma and bilateral mastectomies were
performed.
She accepted a prophylactic BSO 7 years after her initial breast cancer
diagnosis. Pathologic evaluation revealed a single microscopic focus of
epithelial stratiﬁcation, mild cellular atypia, and intense p53 immuno-washings were negative. This unusual histology of a low grade lesionIntroduction
A young woman with a prior diagnosis of bilateral breast cancers,
BRCA1 germline mutation was found to have an atypical, proliferative
lesion in theﬁmbrial end of a fallopian tube found at the timeof bilateral
salpingectomy (BSO). This tubal intra-epithelial lesion did not meet the
criteria for high-grade serous tubal intraepithelial carcinoma (STIC) as it
lacked high-grade atypia and had a low proliferative index (less than
10%). It did, however, show strongdiffuse p53 immunostaining indicative
of a TP53 missense mutation. This was followed by the development of
advanced stage low-grade serous cancer 18months later. This carcinoma,
very atypically for a low-grade serous carcinoma, showed strong diffuse
p53 immuno-reactivity. This case demonstrates the potential for occa-
sional low-grade serous carcinomas, and “low-grade STIC” lesions, to
arise in the setting of germline BRCAmutation. The presence of abnormal
p53 expression may be helpful, diagnostically, in such cases.cology, 600 West 10th Avenue,
hay).
r Inc. This is an open access article ureactivity within the ﬁmbria in one fallopian tube (Fig. 1). Peritoneal
with intense p53 staining was extensively discussed at our center with
the consensus that these ﬁndings did not fulﬁll the criteria for STIC, as
it lacked the marked atypia and high proliferative index of STIC
(Visvanathan et al., 2011). The lesion was diagnosed as tubal epithelial
atypia of uncertain signiﬁcance. Surveillancewas the only post operative
recommendation.
Eighteen months following the BSO, a CT of the abdomen and pelvis
revealed peritoneal carcinomatosis. A core biopsy of an omental nodule
conﬁrmed the presence of a low grade papillary serous neoplasm, ER
positive, with high p53 (Fig. 2). Chemotherapy followed by surgical
debulking was performed. Final histology showed a low-grade serous
carcinoma (Fig. 3). However, her disease progressed 5 months later
and she was initiated on a PARP inhibitor and has remained clinically
stable.Discussion
Recent evidence on the pathogenesis of serous ovarian cancer points
towards there being two diseases: high-grade serous carcinomas and
low-grade serous carcinomas, with the fallopian tube epithelium as the
origin of most high-grade serous cancers, while most low-grade serous
cancers arise from serous borderline tumors. The identiﬁcation of inci-
dental high-grade serous tubal intraepithelial carcinomas (STIC) in the
fallopian tubes of womenwith a genetic predisposition of ovarian cancer
led to the recognition of the tubal origin of HGSC (Kauff et al., 2002).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Single microscopic focus of ﬁmbrial epithelium that exhibits stratiﬁcation, mild atypia and intense p53 immunoreactivity, (A) at 20× magniﬁcation, and (B) at 40× magniﬁcation,
(C) low level of immunostaining for Ki-67, and (D) showing intense and diffuse immunostaining for p53.
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mended as a risk reduction surgery in women with a high risk for the
development of ovarian cancer due to an inherited mutation (e.g. BRCA
1 and BRCA2) (National Comprehensive Cancer Network (NCCN), 2013;
National Institute of Health and Care Excellence (NICE), 2013). The prev-
alence of occult carcinomas in individuals undergoing a prophylactic
oophorectomy at age more than 40 years old doubles as compared to in-
dividuals less than 40 years of age (Finch et al., 2014). Such ﬁndings lend
support to current recommendations for prophylactic surgery at age
35 years old or once child bearing is completed. The cancers that arise
in patients with BRCA1 or BRCA2 germline mutations are almost invari-
ably of high-grade serous type, when modern diagnostic criteria are ap-
plied, with only occasional examples of other cancer cell types reported
(McAlpine et al., 2012; Shaw et al., 2002).
Recognition of occult tubal lesions can be challenging. The rising use
of the Sectioning and Extensively Examining the Fimbria (SEE-FIM)
protocol has resulted in the increased frequency of fallopian tube abnor-
malities reported (Rabban et al., 2009). The diagnostic criteria for STIC
have also evolved, but the consensus is that STIC lesions are uniformly
high-grade, with a high proliferative index (Visvanathan et al., 2011).
Immunostains for the proliferation marker Ki-67 and p53 have beenBA
Fig. 2.Omental biopsy showingmetastatic deposits of invasive low-grade serous carcinoma at lo
characteristic of low-grade serous carcinoma. There is strong diffuse p53 immunoreactivity (C)shown to improve diagnostic reproducibility for STIC in cases that lack
unequivocal high-grade cytological atypia; to support a diagnosis of
STIC there should be high proliferative index (greater than 10%) and
abnormal p53 expression (either complete loss of expression or diffuse
intense nuclear immunoreactivity, with both patterns indicating an un-
derlying TP53 mutation).
Opinions on the treatment of precursor lesions like STICs remain
uncertain. Few data exist on the clinical outcomes of isolated serous
tubal intraepithelial carcinoma (STICS). Wethington et al. reported the
favorable short term clinical outcomes in patients with isolated STICS
where four patients with isolated STICS and negative washings had
gone on to receive adjuvant chemotherapy and there have been no doc-
umented recurrences in this small cohort (Wethington et al., 2013).
There is an increasing move towards the use of staging in STICS. The fa-
vorable short term clinical outcome of cases with negative surgical stag-
ing makes observation without adjuvant chemotherapy reasonable
(Wethington et al., 2013). Even less is known about tubal atypias that
fall short of STIC. The identiﬁcation of p53 mutations in the Cancer Ge-
nome Atlas Project suggested a possible role of p53 aberrations as a pre-
cursor of STIC and serous carcinomas (Integrated Genomic Analysis of
Ovarian Carcinoma, 2011). Cass et al. reported additional alterations areC
wpower (A), andhighpower (B), demonstrating theuniformnuclei and lowmitotic index
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Fig. 3. Omental biopsy showing metastatic deposits of invasive papillary serous adenocarcinoma with numerous psammoma bodies, (A) at low power, (B) at medium power and (C) at
high power. Note the uniform tumor cell nuclei and low mitotic index.
74 W.Y. Chay et al. / Gynecologic Oncology Reports 12 (2015) 72–74required in existing p53 overexpressing epithelium for malignant trans-
formation (Cass et al., 2014). Additional information is required to evalu-
ate the role of p53 alterations in the development of serous carcinoma.
This case demonstrates that the conventional morphological deﬁni-
tions of STIC and high-grade serous carcinoma do not capture all lesions
associatedwith themolecular phenotype of serous neoplasia in patients
with hereditary breast and ovarian cancers (HBOC). Although the
majority of serous neoplasia in these patients will be conventional
STIC or high-grade serous carcinoma (based on routine morphological
assessment), occasional cases overlap morphologically with low-grade
serous carcinoma, despite having thep53molecular abnormalities char-
acteristic of high-grade serous neoplasia. The disease recurrence and
clinical course in our patient further suggests that the presence of intense
p53 was highly suspicious of a precursor of malignancy despite the rela-
tively lowgrade and lowproliferative index,ﬁndings that persisted in the
invasive serous carcinoma that developed subsequently. The index of
suspicion formalignancy should be high in high risk individualswho pre-
sents with tubal atypia having abnormal p53 staining. Regular surveil-
lance and follow-up should be emphasized. The Pelvic-Ovarian cancer
Interception (POINT) Project (http://pointproject.org/POINT/) is a regis-
try set up to address this critical gap in knowledge and add to our under-
standing of the behavior and outcomes of all tubal abnormalities (serous
tubal carcinoma in situ and tubal atypia). This will address the pressing
need for more robust guidelines and greatly aid in the optimal manage-
ment of these patients.Conﬂicts of interest statement
The authors declare that there are no conﬂicts of interests.Acknowledgments
Concept and ideas: Karen A Gelmon, Anna V. Tinker, C. Blake Gilks.
Manuscript writing: All authors.References
Cass, I., Walts, A.E., Barbuto, D., et al., 2014. A cautious view of putative precursors of
serous carcinomas in the fallopian tubes of BRCA mutation carriers. Gynecol. Oncol.
134 (3), 492–497 (Sep).
Finch, A.P., Lubinshi, J., Moller, P., Singer, C.F., Karlan, B., Senter, L., Rosen, B., Maehle, L.,
Ghadirian, P., Cybulski, C., Huzarski, T., Eisen, A., Foulkes, W.D., Kim-Sing, C.,
Ainsworth, P., Tung, N., Lynch, H.T., Neuhausen, S., Metcalfe, K.A., Thompson, I.,
Murphy, J., Sun, P., Narod, S.A., 2014. Impact of oophorectomy on cancer incidence
and mortality in women with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 32 (15),
1547–1553 (May 20).
Integrated Genomic Analysis of Ovarian Carcinoma, 2011. Cancer genomic atlas research
network. Nature 474 (7353), 609–615.
Kauff, N.D., Satagopan, J.M., Robson, M.E., et al., 2002. Risk-reducing salpingo-oophorectomy
in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346 (21), 1609–1615
(Epub 2002 May 20).
McAlpine, J.N., Porter, H., Kobel, M., Nelson, B.H., Prentice, L.M., Kalloger, S.E., Senz, J.,
Milne, K., Ding, J., Shah, S.P., Huntsman, D.G., Gilks, C.B., 2012. BRCA1 and BRCA2 mu-
tations correlate with TP53 abnormalities and presence of immune cell inﬁltrates in
ovarian high-grade serous carcinoma. Mod. Pathol. 25 (5), 740–750 (May, Epub
2012 Jan 27).
National Comprehensive Cancer Network (NCCN), 2013. Genetic/High-Risk familial As-
sessment: Breast and Ovarian 2013 vol. 4 (Available from: http://www.nccn.org/
professionals/physician_gls/pdf/genetics_screening.pdf).
National Institute of Health and Care Excellence (NICE), 2013. Familial Breast Cancer:
Classiﬁcation and Care of People at Risk of Familial Breast Cancer and Management of
Breast Cancer andRelated Risks in Peoplewith a FamilyHistory of Breast Cancer. Nation-
al Institute forHealth andCare Excellence, London (Available from:http://www.nice.org.
uk/guidance/cg164).
Rabban, J.T., Krasik, E., Chen, L.M., et al., 2009. Multistep level sections to detect occult
fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with
BRCA mutations: implications for deﬁning an optimal specimen dissection protocol.
Am. J. Surg. Pathol. 33 (12), 1878–1885 (Dec).
Shaw, P.A., McLaughlin, J.R., Zweemer, R.P., Narod, S.A., Risch, H., Verheijen, R.H., Ryan, A.,
Menko, F.H., Kenemans, P., Jacobs, I.J., 2002. Histopathologic features of genetically
determined ovarian cancer. Int. J. Gynecol. Pathol. 21 (4), 407–411 (Oct).
Visvanathan, K., Vang, R., Shaw, P., et al., 2011. Diagnosis of serous tubal intraepithelial
carcinoma based onmorphologic and immunohistochemical features: a reproducibility
study. Am. J. Surg. Pathol. 35 (12), 1766–1775 (Dec).
Wethington, S.L., Park, K.J., Soslow, R.A., Kauff, N.D., Brown, C.L., Dao, F., Otegbeye, E.,
Sonoda, Y., Abu-Rustum, N.R., Barakat, R.R., Levine, D.A., Garner, G.J., 2013. Clinical
Outcome of Isolated Serous Tubal Intraepthelial carcinomas (STIC). Int. J. Gynecol.
Cancer 23, 1603–1611.
